The latest news from academia, regulators
research labs and other things of interest
Posted: May 11, 2012
Selecta Biosciences Receives 2012 Edison Award's Gold Medal for Best Pharmaceutical Product Innovation
(Nanowerk News) Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has received the prestigious Edison Award for 2012 with the Gold Medal for Best Pharmaceutical Product Innovation. This award recognizes Selecta's novel platform that enables an entirely new way to develop therapeutic and prophylactic vaccines that are highly targeted for improved efficacy and safety. The Edison Awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring America's drive to remain in the forefront of innovation, creativity and ingenuity in the global economy.
Selecta has rapidly translated innovations in nanotechnology and immunology discovered at the Massachusetts Institute of Technology and Harvard Medical School to product candidates that induce antigen-specific immune stimulation and antigen-specific tolerance. Selecta is applying its proprietary Synthetic Vaccine Particle (SVP™) platform to advance a robust pipeline of vaccine candidates for the prevention and treatment of a number of serious diseases, including infectious diseases, smoking cessation, autoimmune diseases and allergies. Selecta's SVP platform is designed to create robust antigen-specific immune responses for superior vaccine effectiveness, while achieving a strong safety profile.
"We are honored to receive this award which underscores the unique value of our technology platform and its game changing potential to make novel vaccines for important human diseases," said Werner Cautreels, PhD, Selecta's President and CEO. "Our proprietary Synthetic Vaccine Particle platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications with the potential for improved efficacy and safety for patients."
About The Edison Awards
The Edison Awards™ recognize the persistence and excellence Thomas Edison personified; qualities which have allowed America to remain in the forefront of innovation, creativity and ingenuity in the global economy. The Edison Awards are granted under the aegis of the Thomas Edison Papers at Rutgers University, a globally recognized research network dedicated to the study of innovation and its application in the 21st century. For more information about The Edison Awards, visit www.edisonawards.com.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta was founded based on complementary research by three academic pioneers, the technology innovations of Professors Robert Langer and Omid Farokhzad combined with the immunological insights of Professor Ulrich von Andrian. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic and prophylactic applications while offering the potential of improved efficacy and safety profiles. Selecta's fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta's SVP™ platform technology is readily adaptable to enable diverse vaccines and the company has created antigen-specific targeted Synthetic Vaccine Particles (tSVP™) and antigen-specific targeted tolerogenic Synthetic Vaccine Particles (t2SVP™).
Targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples for applications include cancer, infectious diseases and addiction. Targeted tolerogenic Synthetic Vaccine Particles (t2SVP™) are designed to induce antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies and transplant rejection.
Selecta's pipeline currently contains vaccines for smoking cessation, malaria, and universal influenza and tolerogenic immunotherapies for type-1 diabetes and allergies.
Building on the company's novel approach, Selecta's product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases. Selecta Biosciences, Inc. is based in Watertown, Massachusetts, USA. For more information, please visit www.selectabio.com.